



Ironwood Pharmaceuticals, Inc.
Investor Relations Department
301 Binney Street, 2nd floor
Cambridge, MA 02142
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: IRWD ¹

Last Trade:	15.21
Trade Time:	4:00 PM ET Dec 14, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	13.43 - 19.94
Volume	N/A
Market Cap. (\$M)	2,059.282
Shares Out (M)	135.390

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

At Ironwood, we're focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 4, 2017

[Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects](#)

Nov 28, 2017

[Ironwood Pharmaceuticals Strengthens Executive Leadership Team](#)

Nov 2, 2017

[Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update](#)

Nov 1, 2017

[Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference](#)

Oct 30, 2017

[Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 22, 2017

[Annual Report \(10-K\)](#)

Apr 18, 2017

[Definitive Proxy Statement](#)

Nov 2, 2017

[Quarterly Report \(10-Q\)](#)

Aug 3, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)